The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Tambocor     N-(2-piperidylmethyl)-2,5- bis(2,2,2...

Synonyms: Flecaine, Flecainida, flecainide, Flecainidum, Ic Flecainide, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of flecainide


Psychiatry related information on flecainide


High impact information on flecainide

  • The mechanisms underlying the excess mortality during treatment with encainide or flecainide remain unknown [7].
  • Flecainide thus appears to be a highly effective and well-tolerated antiarrhythmic agent with favorable pharmacokinetics [1].
  • Hospital monitoring during initial therapy is recommended, and flecainide should be used with caution, if at all, in patients with structural heart disease [5].
  • Adverse cardiac reactions (proarrhythmia or sinus node suppression) attributable to flecainide occurred in 11 of 63 patients (17%); in 9 (82%) of these 11 patients, events were detected during either in-hospital monitoring or the electrophysiologic study done before discharge [5].
  • Isoproterenol reversed the effects of flecainide therapy in 11 of 21 patients; 7 of the 11 patients had spontaneous clinical recurrences of tachycardia or palpitations during the follow-up period, but these symptoms occurred in only 1 of 10 patients who did not show isoproterenol-induced reversal (P = 0.02) [5].

Chemical compound and disease context of flecainide


Biological context of flecainide


Anatomical context of flecainide


Associations of flecainide with other chemical compounds


Gene context of flecainide

  • CONCLUSIONS: The functional properties of Kv4.2, especially the flecainide sensitivity, resemble those of ITO in rat (and human) myocytes better than those of Kv1 [24].
  • Na(+) channel blockers such as flecainide have found renewed usefulness in the diagnosis and treatment of two clinical syndromes arising from inherited mutations in SCN5A, the gene encoding the alpha subunit of the cardiac voltage-gated Na(+) channel [25].
  • The CYP2D6 polymorphism did not appear to influence flecainide disposition kinetics or electrocardiographic effects at steady state [26].
  • The ERP of the right ventricle increased from 251 +/- 27 ms during the control study to 267 +/- 34 ms on flecainide (P less than 0.01) [27].
  • The binding of flecainide to open channels was further investigated in a non-inactivating mutant of Nav1 [28].

Analytical, diagnostic and therapeutic context of flecainide


  1. Oral flecainide acetate for the treatment of ventricular arrhythmias. Anderson, J.L., Stewart, J.R., Perry, B.A., Van Hamersveld, D.D., Johnson, T.A., Conard, G.J., Chang, S.F., Kvam, D.C., Pitt, B. N. Engl. J. Med. (1981) [Pubmed]
  2. Ventricular tachycardia associated with flecainide. Muhiddin, K., Nathan, A.W., Hellestrand, K.J., Banim, S.O., Camm, A.J. Lancet (1982) [Pubmed]
  3. Flecainide-associated pneumonitis. Akoun, G.M., Cadranel, J.L., Israel-Biet, D., Gauthier-Rahman, S. Lancet (1991) [Pubmed]
  4. Flecainide-associated interstitial pneumonitis. Hanston, P., Evrard, P., Mahieu, P., Wallemacq, P., Friob, M., Hassoun, A. Lancet (1991) [Pubmed]
  5. Safety and efficacy of oral flecainide therapy in patients with atrioventricular re-entrant tachycardia. Cockrell, J.L., Scheinman, M.M., Titus, C., Helmy, I., Langberg, J.J., Lee, M.A., Griffin, J.C. Ann. Intern. Med. (1991) [Pubmed]
  6. Dysarthria and visual hallucinations due to flecainide toxicity. Ramhamadany, E., Mackenzie, S., Ramsdale, D.R. Postgraduate medical journal. (1986) [Pubmed]
  7. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. Echt, D.S., Liebson, P.R., Mitchell, L.B., Peters, R.W., Obias-Manno, D., Barker, A.H., Arensberg, D., Baker, A., Friedman, L., Greene, H.L. N. Engl. J. Med. (1991) [Pubmed]
  8. Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. Herre, J.M., Titus, C., Oeff, M., Eldar, M., Franz, M.R., Griffin, J.C., Scheinman, M.M. Ann. Intern. Med. (1990) [Pubmed]
  9. Echo-wave termination of ventricular tachycardia. A common mechanism of termination of reentrant arrhythmias by various pharmacological interventions. Brugada, J., Boersma, L., Abdollah, H., Kirchhof, C., Allessie, M. Circulation (1992) [Pubmed]
  10. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Anderson, J.L., Platia, E.V., Hallstrom, A., Henthorn, R.W., Buckingham, T.A., Carlson, M.D., Carson, P.E. Circulation (1994) [Pubmed]
  11. Flecainide and amiodarone: combined therapy for refractory tachyarrhythmias in infancy. Fenrich, A.L., Perry, J.C., Friedman, R.A. J. Am. Coll. Cardiol. (1995) [Pubmed]
  12. Block of delayed rectifier potassium current, IK, by flecainide and E-4031 in cat ventricular myocytes. Follmer, C.H., Colatsky, T.J. Circulation (1990) [Pubmed]
  13. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group. Henthorn, R.W., Waldo, A.L., Anderson, J.L., Gilbert, E.M., Alpert, B.L., Bhandari, A.K., Hawkinson, R.W., Pritchett, E.L. Circulation (1991) [Pubmed]
  14. Beta-adrenergic augmentation of flecainide-induced conduction slowing in canine Purkinje fibers. Cragun, K.T., Johnson, S.B., Packer, D.L. Circulation (1997) [Pubmed]
  15. Cardioprotective effects of various class I antiarrhythmic drugs in canine hearts. Hanaki, Y., Sugiyama, S., Hieda, N., Taki, K., Hayashi, H., Ozawa, T. J. Am. Coll. Cardiol. (1989) [Pubmed]
  16. Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits. Restivo, M., Yin, H., Caref, E.B., Patel, A.I., Ndrepepa, G., Avitable, M.J., Assadi, M.A., Isber, N., el-Sherif, N. Circulation (1995) [Pubmed]
  17. Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts. Coromilas, J., Saltman, A.E., Waldecker, B., Dillon, S.M., Wit, A.L. Circulation (1995) [Pubmed]
  18. Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry? Krishnan, S.C., Antzelevitch, C. Circulation (1993) [Pubmed]
  19. Effects of flecainide on ectopic atrial automaticity and conduction. Windle, J.R., Witt, R.C., Rozanski, G.J. Circulation (1993) [Pubmed]
  20. Effects of flecainide and quinidine on human atrial action potentials. Role of rate-dependence and comparison with guinea pig, rabbit, and dog tissues. Wang, Z.G., Pelletier, L.C., Talajic, M., Nattel, S. Circulation (1990) [Pubmed]
  21. Sodium channel block produces opposite electrophysiological effects in canine ventricular epicardium and endocardium. Krishnan, S.C., Antzelevitch, C. Circ. Res. (1991) [Pubmed]
  22. Flecainide and amiodarone interaction. Shea, P., Lal, R., Kim, S.S., Schechtman, K., Ruffy, R. J. Am. Coll. Cardiol. (1986) [Pubmed]
  23. Electrophysiologic effects of sodium channel blockade on anisotropic conduction and conduction block in canine myocardium: preferential slowing of longitudinal conduction by flecainide versus disopyramide or lidocaine. Kondo, T., Yamaki, M., Kubota, I., Tachibana, H., Tomoike, H. J. Am. Coll. Cardiol. (1997) [Pubmed]
  24. Electrophysiological and pharmacological correspondence between Kv4.2 current and rat cardiac transient outward current. Yeola, S.W., Snyders, D.J. Cardiovasc. Res. (1997) [Pubmed]
  25. Channel openings are necessary but not sufficient for use-dependent block of cardiac Na(+) channels by flecainide: evidence from the analysis of disease-linked mutations. Liu, H., Tateyama, M., Clancy, C.E., Abriel, H., Kass, R.S. J. Gen. Physiol. (2002) [Pubmed]
  26. Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism. Tennezé, L., Tarral, E., Ducloux, N., Funck-Brentano, C. Clin. Pharmacol. Ther. (2002) [Pubmed]
  27. Efficacy of flecainide in pacing-induced sustained ventricular tachyarrhythmias: correlation to clinical parameters and tachycardia-characteristics. Podczeck, A., Borggrefe, M., Bartels, K., Breithardt, G. Eur. Heart J. (1989) [Pubmed]
  28. State-dependent trapping of flecainide in the cardiac sodium channel. Ramos, E., O'leary, M.E. J. Physiol. (Lond.) (2004) [Pubmed]
  29. Drug therapy. Flecainide. Roden, D.M., Woosley, R.L. N. Engl. J. Med. (1986) [Pubmed]
  30. Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias. Brugada, J., Boersma, L., Kirchhof, C., Allessie, M. Circulation (1991) [Pubmed]
  31. Amplification of flecainide-induced ventricular conduction slowing by exercise. A potentially significant clinical consequence of use-dependent sodium channel blockade. Ranger, S., Talajic, M., Lemery, R., Roy, D., Nattel, S. Circulation (1989) [Pubmed]
  32. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Anderson, J.L., Gilbert, E.M., Alpert, B.L., Henthorn, R.W., Waldo, A.L., Bhandari, A.K., Hawkinson, R.W., Pritchett, E.L. Circulation (1989) [Pubmed]
WikiGenes - Universities